Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect (Q58970743)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Ian Reid

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1

John A Eisman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

6

Rene Rizzoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Henry G Bone

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

David J Hosking

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Heinrich Resch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Nadia Verbruggen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Carolyn M Hustad

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Carolyn DaSilva

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Romana Petrovic

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Arthur C Santora

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

B Avery Ince

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Antonio Lombardi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

Journal of Bone and Mineral Research

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

242-251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

Cathepsin K inhibitors: a novel target for osteoporosis therapy

11 February 2020

cites work

1 reference

A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

21 January 2018

1 reference

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.

21 January 2018

1 reference

Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7.

21 January 2018

1 reference

Characterization of the bone phenotype in ClC-7-deficient mice

21 January 2018

1 reference

Ion transporters involved in acidification of the resorption lacuna in osteoclasts

21 January 2018

1 reference

The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics

21 January 2018

1 reference

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity

21 January 2018

1 reference

Effect of cathepsin k inhibitor basicity on in vivo off-target activities.

21 January 2018

1 reference

Drug-induced morphea: report of a case induced by balicatib and review of the literature

21 January 2018

1 reference

Bone density, strength, and formation in adult cathepsin K (-/-) mice

21 January 2018

1 reference

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

Are nonresorbing osteoclasts sources of bone anabolic activity?

21 January 2018

1 reference

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

21 January 2018

1 reference

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Changes in bone density and turnover after alendronate or estrogen withdrawal.

21 January 2018

1 reference

Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study.

21 January 2018

1 reference

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JBMR.212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20740685%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference